Carbohydrate derivatives fight against the malaria parasite as anti-plasmodial agents

Carbohydrate derivatives fight against the malaria parasite as anti-plasmodial agents.
In this review, the importance of carbohydrate derivatives of different classes of compounds as possible antimalarials with emphasis on mode of action, rational design, and SAR with improved efficacy are discussed. The new candidates with novel modes of action are potent antimalarial drug candidates without any parasitic resistance.

See the full article here!

Multifunctional Cyclodextrins Carriers for Pulmonary Drug Delivery: Prospects and Potential

today’s cyclodextrin:
is about multifunctional CD for Pulmonary Drug Delivery.
The paper focuses on inhaled CDs-based carriers, pulmonary applications of CDs with particular emphasis on aerosolization fate, powder dispersion behavior, pharmacokinetic outcomes, and long-term stability performance and the prospects and potential for translating inhaled CDs-based carrier systems. The bottom-line marks CD-based carriers for the growth of pulmonary medicines in the upcoming years.
Dr. Piyush Pradeep Mehta & Dr. Vividha Dhapte

See the full article here!

Recording of the webinar Cyclodextrins in Biopharma available

Dear Colleagues,

We are happy to share the recording of the first Roquette-CarboHyde joint webinar, Cyclodextrins in Biopharma is available on Youtube.

You can find the recording here:

After watching the video, we would be grateful for your feedback about the event:

You will find the questionnaire here:

the CarboHyde team

Mannosylated glycans impair normal T-cell development by reprogramming commitment and repertoire diversity

Mannosylated glycans impair normal T-cell development.
Gabriel RabinovichSalomé S. Pinho et al. discovered stage-specific glycome compositions during T-cell development in human and murine thymocytes, as well as dynamic alterations. In conclusion, mannosylated thymocytes lead to a dysregulation in T-cell development that is associated with inflammation susceptibility.

See the full article here on!

Oral polysaccharide for treating inflammatory bowel disease and preparation method therefor

Great invention using refined heparin-like polysaccharides for the treatment of inflammatory bowel disease and related complications. After the de-anticoagulant treatment and enzymatic hydrolysis of raw heparin, the heparin-like polysaccharides are separated by using a gel size exclusion chromatography column and specific oligosaccharides are used in the preparation of medicaments.
Further potential target diseases include irritable bowel syndrome, arthritis and other extraintestinal complications, including ankylosing spondylitis, gangrenous pyoderma disease, erythema nodosum, iritis, uveitis, episcleritis, primary sclerosing cholangitis, and rheumatoid arthritis.

See the full patent on Espacenet

Cyclodextrin-based polyrotaxanes and protein hybrids as three-dimensional printing inks

today’s cyclodextrin:
we have already talked about both rotaxanes and CD-supported 3D printing Now Dartmouth College, an invention form Chenfeng KeQianming LinMiao Tang and Li Longyu presents the combination of the two.
Rotaxanes have numerous applications, including applications in three-dimensional printing. However, current rotaxanes have numerous limitations in terms of fabrication and properties optimal for 3D printing. For instance, the synthesis of cyclodextrin-based three-dimensional (3D)—printable polypseudorotaxanes, which are formed by threading α-cyclodextrins (α-CDs) onto linear polyethylene glycol (PEG), requires the use of high molecular weight PEG with a minimal molecular weight of 10 k Pa.
Rotaxanes presented in this patent overcome such handicaps and offer a feasible solution.

See the full patent here on Espacenet

CarboHyde appoints Tamas Sohajda as CEO of the company

CarboHyde, a pharmaceutical company specializing in carbohydrate chemistry and innovative carbohydrate applications, today announced the appointment of its new CEO Tamas Sohajda, replacing the founder and former CEO, József Tóth. The reasons for the decision are captured in József’s personal memorandum below.

Dear colleagues, friends, and valued partners,

Today, I am writing to share an important announcement that marks a significant turning point in my life’s journey. After an incredible adventure at the helm of our beloved biotech startup CarboHyde, I have made the decision to retire from my role as CEO. I am stepping down from this position but will stay in the company as Chief Medical Officer.

It has become clear that dedicating myself both to a full-time consultant position at Semmelweis University and, meanwhile, leading CarboHyde is simply not feasible at the same time, as the expansion and development of the company demand an increasing amount of time, effort, and focus. As a result, I have come to the difficult decision to retire from my position as CEO in order to ensure that the company continues to thrive and reach its full potential under new leadership.

Words cannot express the deep gratitude and immense pride I feel as I reflect upon the extraordinary experiences we have shared throughout this incredible voyage. It has been an honor and a privilege to work alongside such remarkable individuals who have inspired me every single day.

Additionally, I would like to take a moment to express my utmost confidence in the capabilities of our incoming CEO. Tamás Sohajda, a brilliant and accomplished leader, will undoubtedly bring a fresh perspective and a wealth of expertise to guide our company into its next phase of growth. I have had the pleasure of working closely with Tamás and have witnessed firsthand his exceptional leadership qualities and strategic acumen. His deep understanding of the biotech industry, combined with his visionary thinking, will be invaluable assets as we steer CarboHyde toward new horizons. I have no doubt that Tamás will continue to drive our company towards even greater success.

In conclusion, I would like to express my deepest gratitude to each and every one of you.

With warm regards,

József Tóth

Founder and former CEO of CarboHyde

Carbohydrate Chronicles – A podcast about glycoscientists

We are happy to present Carbohydrate Chronicles, a podcast about Glycoscience and glycoscientists. In this show, via a series of interviews, we explore the world of carbohydrate science and innovation from the personal point of view hosted by Tamas Sohajda, a member of CarboHyde’s scientific team.

We find it important and essential to get familiar with the research and the researcher itself. In our series, we invite key opinion leaders of the glycoscience field both from academia and industry, to work on various angles of carbohydrates. Over 16 weeks, we will publish a new episode of 16 interviews altogether as part of our first season. All recordings will be available online at Apple Podcast, Spotify, YouTube, and Google Podcasts.

Learn more about the episodes here!

Carbohydrate Chronicles